The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAxsome Therapeutics reported robust financial results for the first quarter of 2026, with revenue surging 57.4% year-over-year to reach $191.2 million. This significant growth was primarily driven by a 59% increase in sales of its flagship drug, Auvelity, which recently secured FDA approval for treating agitation associated with Alzheimer's disease. Amidst this positive momentum, the company's stock approached its 52-week high of $234.29, prompting the COO to sell 233 shares at a price of $228.18. While the company faces a widening net loss, the regulatory milestone for Auvelity marks a critical expansion of its market potential in the biotechnology sector. Investors remain focused on the company's ability to scale its commercial operations following these latest clinical and regulatory successes. The combination of strong top-line growth and portfolio expansion underscores Axsome's current upward trajectory.